| Literature DB >> 26828466 |
Bing Hu1, Hong-Mei An2, Shuang-Shuang Wang3, Jin-Jun Chen4, Ling Xu5.
Abstract
Traditional Chinese Medicines, unique biomedical and pharmaceutical resources, have been widely used for hepatocellular carcinoma (HCC) prevention and treatment. Accumulated Chinese herb-derived compounds with significant anti-cancer effects against HCC have been identified. Chinese herbal compounds are effective in preventing carcinogenesis, inhibiting cell proliferation, arresting cell cycle, inducing apoptosis, autophagy, cell senescence and anoikis, inhibiting epithelial-mesenchymal transition, metastasis and angiogenesis, regulating immune function, reversing drug resistance and enhancing the effects of chemotherapy in HCC. This paper comprehensively reviews these compounds and their effects on HCC. Finally, the perspectives and rational application of herbal compounds for HCC management are discussed.Entities:
Keywords: Chinese herbal compound; hepatocellular carcinoma; phytopharmacology; prevention; treatment
Mesh:
Substances:
Year: 2016 PMID: 26828466 PMCID: PMC6274246 DOI: 10.3390/molecules21020142
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Anti-cancer effects of herbal compounds against hepatocarcinoma. 1, Ursolic acid; 2, Penta-acetyl geniposide; 3, Curcumin; 4, Matrine; 5, Solamargine; 6, Ponicidin; 7, Tetrandrine; 8, Baicalein; 9, Bufalin; 10, Ganoderiol F; 11, Rhein; 12, Oridonin; 13, Curcumol; 14, Salvianolic acid B; 15, Steroidal saponins; 16, Davidiin; 17, β-Elemene; 18, Ardipusilloside-I; 19, Raddeanin A; 20, Tanshinone IIA; 21, Cordycepin; 22, Huaier polysaccharides; 23, Astragaloside II; 24, Oroxylin A; 25, Tetramethylpyrazine; 26, Arecoline; 27, Artemisinin; 28, Resveratrol; 29, Isofraxidin; 30, Astragalus polysaccharides; 31, Radix Glycyrrhizae polysaccharides; 32, Lycium barbarum polysaccharide; 33, Polysaccharides from Artemisia annua L.; 34, Gastrodin; 35, Shikonin; 36, Gekko sulfated polysaccharide-protein complex; 37, Gekko-sulfated glycopeptide; 38, Pedicularioside G; 39, Vitexin compound 1.
Herbal compounds that inhibit hepatocarcinogenesis.
| Compounds | Herbs | Effects | Targets/Molecular Events | Ref. |
|---|---|---|---|---|
| Ursolic acid | ↓ DEN induced hepatocarcinogenesis | ↓ Oxidative stress | [ | |
| Penta-acetyl geniposide | ↓ AFB1 induced hepatocarcinogenesis | ↓ GGT foci | [ | |
| Curcumin | ↓ DEN induced hepatocarcinogenesis | ↓ p21(ras), PCNA and CDC2 | [ | |
| Berberine | ↓ DEN-plus-PB induced hepatocyte proliferation | ↓ iNOS, cytochrome P450, CYP2E1 and CYP1A2 | [ | |
| Saikosaponin-d | ↓ DEN induced hepatocarcinogenesis | ↓ COX-2 and C/EBPβ | [ | |
| Gomisin A | the fruits of | ↓ 3′-MeDAB induced hepatocarcinogenesis | Unknown | [ |
| Tea polyphenols and tea pigments | Tea | ↓ DEN induced hepatocarcinogenesis | ↑ p21WAF1 and Bax, ↓ Bcl-2 | [ |
| Astragalosides, Astragalus polysaccharide and salvianolic acids | ↓ DEN induced hepatocarcinogenesis | ↓ GST-P and α-SMA | [ |
↓ Inhibit or down-regulate, ↑ up-regulate; DEN, diethylnitrosamine; AFB1, aflatoxin B1; PB, phenobarbital; 3′-MeDAB, 3′-methyl-4-dimethylaminoazobenzene.
Direct anticancer effects of herbal compounds against hepatocarcinoma.
| Compounds | Herbs | Effects | Targets/Molecular Events | Ref. | ||
|---|---|---|---|---|---|---|
| Salvianolic acid B | ↓ HepG2 cell proliferation | ↓ CYP3A4 and CYP1A2, ↑ GST | [ | |||
| Steroidal saponins | ↓ SMMC7721 and Bel-7402 cell proliferation | Unknown | [ | |||
| Davidiin | ↓ Hepatocellular tumor growth | ↓ EZH2 | [ | |||
| β-Elemene | ↓ H22 tumor growth | ↑ Histone H1 | [ | |||
| Ardipusilloside-I | ↓ SMMC-7721 tumor growth; ↓ invasion and metastasis in HCC | Unknown; ↓ MMP-9 and -2, ↑ Rac1 and E-cadherin | [ | |||
| Raddeanin A | ↓ H22 tumor growth | Unknown | [ | |||
| Indole-3-acetonitrile-4-methoxy-2-C-β-
| ↓ HepG2 cell proliferation | Unknown | [ | |||
| Pinocembrin-7-
| ↓ Hepatocarcinoma cell growth | Unknown | [ | |||
| 20( | ↓ proliferation, ↑ apoptosis, arrest cell cycle at the G1 phase | ↑ p53 phosphorylation, activate caspase-3 | [ | |||
| 20( | ↑ apoptosis, ↓ liver cancer growth | ↓ PCNA, ↑ TNF | [ | |||
| Gypenoside | ↓ proliferation, ↑ apoptosis in Hep3B and HA22T cells | Unknown | [ | |||
| Isorhamnetin | ↓ proliferation, ↑ apoptosis in Bel-7402 cells | Unknown | [ | |||
| Liquiritigenin | ↑ apoptosis, ↓ H22 tumor growth | Unknown | [ | |||
| N-butylidenephthalide | ↑ apoptosis in HepG2 and J5 cells, ↓ cell and tumor growth | ↑ Nurr1, NOR-1, Nur77, CREB, caspase-9 and caspase-3, ↓ phosphor-AKT | [ | |||
| ↓ proliferation, ↑ apoptosis, arrest cell cycle at S phase in QGY7703 cells | ↑ Intracellular Ca2+ | [ | ||||
| Apigenin | ↓ proliferation, ↑ apoptosis, arrest cell cycle at G2/M phase in Huh7 cells | ↑ 1336 genes, ↓ 428 genes | [ | |||
| Icariin | ↑ apoptosis in SMMC-7721 cells | ↑ ROS, JNK, Bax/Bcl-2 and caspase | [ | |||
| Icaritin | ↑ apoptosis in HepG2 cells | ↑ JNK1, Bax/Bcl-2 and caspase-3 | [ | |||
| Oxymatrine | ↓ proliferation, ↑ apoptosis, arrest cell cycle at S and G2/M phase in SMMC-7721 cells | ↓ Bcl-2, ↑ p53 | [ | |||
| Scutellarin | ↓ proliferation, ↑ apoptosis in HepG2 cells | ↓ ROS, STAT3, Bcl-XL and Mcl-1 | [ | |||
| Sarsasapogenin | ↓ proliferation, ↑ apoptosis, arrest cell cycle at G2/M phase in HepG2 cells | Unknown | [ | |||
| Pheophorbide a | ↑ apoptosis in HepG2 and Hep3B cells | ↓ Bcl-2, ↑ pro-caspase 3 and pro-caspase 9 | [ | |||
| Solamargine | ↓ proliferation, ↑ apoptosis, arrest cell cycle at G2/M phase in SMMC-7721 and HepG2 cells | ↑ caspase-3 | [ | |||
| Ponicidin | ↓ proliferation, ↑ apoptosis in QGY-7701 and HepG-2 cells | ↓ Survivin and Bcl-2, ↑ Bax | [ | |||
| Paeonol | ↓ tumor growth, ↑ apoptosis in HepA-hepatoma bearing mice | ↓ Bcl-2, ↑ Bax, IL-2 and TNF-alpha | [ | |||
| Cryptotanshinone, dihydrotanshinone, tanshinone I, tanshinone IIA | ↑ apoptosis in HepG2 cells | ↑ ROS | [ | |||
| Resveratrol-4- | ↓ proliferation, ↑ apoptosis in SMMC-7721 cells | ↑ caspase-3 and -9, p-JNK, ↓ p-ERK | [ | |||
| Tubeimoside I | ↓ proliferation, ↑ apoptosis, arrest cell cycle at G2/M phase in HepG2 cells | ↑ caspase-3 and -9, Bax/Bcl-2 | [ | |||
| Norcantharidin | Mylabris (Ban-Mao) | ↓ proliferation, ↑ apoptosis in HepG2 cells | ↑ ROS, caspase-3 and -9, and Bax, ↓ Bcl-2 | [ | ||
| Resveratrol-4- | ↓ proliferation, ↑ apoptosis in SMMC-7721 cells | ↑ caspase-3 and -9, p-JNK, ↓ p-ERK | [ | |||
| Toosendanin | ↓ proliferation, ↑ apoptosis in SMMC-7721 and Hep3B cells | ↑ Bax, ↓ Bcl-2 | [ | |||
| Honokiol | ↑ apoptosis in liver cancer cells | ↓ Bcl-X(L), Bcl-2, procaspase-3 and -9, ↑ MAPK and active caspase-3 | [ | |||
| Magnolol | ↑ apoptosis in HepG2 cells | ↑ caspase-3, -8, and -9, ↓ Bcl-2 | [ | |||
| Oleanolic acid and ursolic acid | The fruit of | ↓ proliferation and adhesion, ↑ apoptosis in liver cancer cells | ↑ caspase-3 and -8, ↓ Na(+)-K(+)-ATPase activity, VEGF and ICAM-1 | [ | ||
| Chrysophanol | ↓ proliferation, ↑ necrosis in J5 cells | ↓ ATP level, ↑ ROS and lactate dehydrogenase activity | [ | |||
| Rhein | ↑ apoptosis in HepG2 cells; ↓ proliferation, ↑ apoptosis, arrest cell cycle at S phase in Bel-7402 cells | ↑ caspase-3; ↑ caspase-3, ↓ c-Myc | [ | |||
| Vitexin compound 1 | ↓ proliferation, ↑ apoptosis in liver cancer cells | ↑ caspase-3, -8 and -9, FOXO3a, Bim, TRAIL, DR4 and DR5, ↓ phosphorylation of AKT and ERK1/2 | [ | |||
| Quercetin | ↓ proliferation, ↑ apoptosis in HA22T/VGH cells | ↑ ROS | [ | |||
| Gambogic acid | ↓ proliferation, ↑ apoptosis in SMMC-7721 cells | ↑ Bax, ↓ Bcl-2 | [ | |||
| Flavonoids | ↓ proliferation, ↑ apoptosis, arrest cell cycle at S phase in SMMC-7721 cells | Unknown | [ | |||
| TSP02 | ↓ proliferation, migration and invasiveness, ↑ apoptosis in HepG2 cells | ↓ CDK1, 2, 4, and TGF-beta1, ↑ Caspase-8 and E-cadherin | [ | |||
| Bufothionine | ↓ proliferation, ↑ arrest cell cycle at G2/M phase in hepatocarcinoma cells | Unknown | [ | |||
| Oridonin | ↓ proliferation, ↑ apoptosis, arrest cell cycle at G2/M phase in HepG2 cells | ↑ p-JNK, p-p38, p-p53, p21, cyclin B1/p-Cdc2 (Tyr15), caspase-9 and -3, ↓ p-ERK | [ | |||
| Curcumol | ↓ proliferation, arrest cell cycle at G1 phase in HepG2 cells | ↑ pRB1, cyclin D1, CDK2, CDK8, p27KIP1, p53 and p21WAF1, ↓ cyclin A1 | [ | |||
| Saikosaponin d | ↓ proliferation, ↑ apoptosis, arrest cell cycle at G1 phase in HepG2 and Hep 3B cells | ↑ p53, p21/WAF1, Fas/APO-1, mFasL, sFasL, Bax and IkappaBalpha, ↓ NF-kappaB and Bcl-XL | [ | |||
| Waltonitone | ↓ proliferation, arrest cell cycle at S phase in Bel-7402 cells | ↑ Akt and ERK1/2 phosporylation | [ | |||
| Nobiletin | ↓ proliferation, ↑ apoptosis, arrest cell cycle at G2 phase in SMMC-7721 cells | ↑ Bax and caspase-3, ↓ Bcl-2 and COX-2 | [ | |||
| Matrine | ↓ proliferation, ↑ apoptosis and autophagy, arrest cell cycle at G1 phase in HCC cells; ↓ invasion in SMMC-7721 cells | ↑ Bax/Bcl-2 and Beclin 1; ↓ MMP-9 and NF-κB | [ | |||
| Berberine | ↑ apoptosis, arrest cell cycle at G1 phase in HuH7 cells; ↑ apoptosis and autophagy in HepG2 cells | ↓ PCNA, Bid and Bcl-2, ↑ caspase-3 and -7; ↑ AMPK, ↓ mTORC1 | [ | |||
| Baicalein | ↑ apoptosis, arrest cell cycle at G2/M phase in J5 cells; ↓ proliferation, ↑ apoptosis and autophagy in SMMC7721 cells | ↑ caspase-9 and -3, and Bax/Bcl-2 ratio; ↑ Βeclin 1, ↓ CD147 | [ | |||
| Oroxylin-A | ↓ proliferation, ↑ apoptosis and autophagy in HepG2 cells; reverse drug resistance and enhance apoptosis inducing effect of Paclitaxel in drug resistant HepG2 cells | Induction of Bax translocation, activation and oligomerization, ↑ Βeclin 1, ↓ PI3K-PTEN-Akt-mTOR signaling pathway; ↓ Integrinβ1 | [ | |||
| Shikonin | ↑ apoptosis in Huh7 and BEL7402 cells; ↑ autophagy in HCC cells; ↓ proliferation and migratory ability on HepJ5 and Mahlavu cells | ↑ ROS, ↓ Akt and RIP1/NF-κB; ↑ ROS and ERK, ↓ RIP pathway; ↓ MMP-2 and -9, vimnetin, AKT and IκB phosphorylation, NF-κB | [ | |||
| Curcumin | ↑ apoptosis in Huh7 cells; ↑ apoptosis and autophagy in HepG2 cells; ↓ proliferation, EMT and migration in hypoxic HepG2 cells | ↑ p38, FasL and caspase-3; ↑ caspase-3, ↓ Bcl-2/Bax; ↓ HIF-1alpha | [ | |||
| Resveratrol | ↓ proliferation, ↑ apoptosis in Hepa 1-6 cells; ↓ proliferation, ↑ apoptosis and autophagy, arrest cell cycle at S phase in HuH7 cells; ↓ invasion in HCC cells | ↑ROS and caspase-3; ↑ p21/WAF1, Atg5, Atg7, Atg9, and Atg12, ↓ cyclin E, cyclin A, CDK2, phospho-ERK and phospho-p38; ↓ MMP-9 | [ | |||
| Bufalin and cinobufagin | Toad skin and venom | ↑ apoptosis in HepG2 cells (Bufalin and cinobufagin); ↑ apoptosis and autophagy in HepG2 cells (Bufalin) | ↑ Fas, Bax and Bid, caspase-3, -8, -9 and -10, ↓ Bcl-2 (Bufalin and cinobufagin; ↑ Βeclin 1 and AMPK phosphorylation, ↓ p62 and mTOR signaling (Bufalin) | [ | ||
| Tetrandrine | ↓ proliferation, ↑ apoptosis and autophagy, arrest cell cycle at G2/m phase in liver cancer cells | ↑ ROS, ERK MAP kinase and ATG7, ↓ Akt | [ | |||
| Arenobufagin | Toad venom | ↑ apoptosis and autophagy in HepG2 cells | ↑ Bax/Bcl-2, ↓ PI3K/Akt/mTOR pathway | [ | ||
| Allicin | Garlic | ↓ proliferation, ↑ autophagy in HepG2 cells | ↑ AMPK/TSC2 and Beclin-1 signaling, ↓ p53, the PI3K/mTOR signaling and Bcl-2 | [ | ||
| Galangin | ↓ proliferation, ↑ apoptosis and autophagy in HepG2 cells | ↑ p53 | [ | |||
| Kaempferol | ↓ proliferation, ↑ autophagy, arrest cell cycle at G2/M phase in SK-HEP-1 cells | ↑ p-AMPK, LC3-II, Atg 5, Atg 7, Atg 12 and beclin 1, ↓CDK1, cyclin B, p-AKT and p-mTOR | [ | |||
| EGCG | Tea | Inhibit autophagy to enhance anti-cancer effects of doxorubicin in Hep3B cells | ↓ Βeclin 1 and Atg5 | [ | ||
| Elemene injection | Induce autophagy and prevent HepG2 cells from undergoing apoptosis | ↓ Bcl-2/Bax and LC3 I/LC3 II ratio | [ | |||
| Ganoderiol F | ↓ proliferation, ↑ cell senescence in HepG2 cells | ↑ EKR and p16 | [ | |||
| Arecoline | ↑ anoikis in HA22T/VGH cells | ↑ Bax, caspase-3 and Rho/Rock activation, ↓ beta1-integrin, IL-6, STAT3 and p190RhoGAP phosphorylation, SHP2, Bcl-XL and Bcl-2 | [ | |||
| Tanshinone II-A | ↓ proliferation, ↑ apoptosis, arrest cell cycle at G0/G1 phase in SMMC-7721 cells; ↓ EMT and metastasis in HCC; ↓ migration and invasion in HCC cells | ↓ Bcl-2 and c-myc, ↑ Fas, Bax and p53; ↑ VEGFR1/PDGFR; ↓ MMP-2 and -9, NF-κB | [ | |||
| Dihydroartemisinin | ↓ proliferation, ↑ apoptosis, arrest cell cycle at G2/M phase in HCC cells; ↓ invasion and metastasis in HCC cells | ↑ p21, caspase-9 and -3 , Noxa and active Bak, ↓ cyclin B, CDC25C and Mcl-1; ↓ MMP2, ↑ TIMP2, Cdc42 and E-cadherin | [ | |||
| Cordycepin | ↓ proliferation, EMT and migration/invasion | ↓ integrin α3, integrin α6, integrin β1 and phosphorylated FAK | [ | |||
| Polysaccharides | Huaier | ↓ proliferation, EMT, adhesion, migration and invasion in MHCC97-H cells | ↓ AEG-1 | [ | ||
| Platycodin D | ↓ proliferation, adhesion, migration and invasion in HCC cells | ↑ Bax, ↓ survivin | [ | |||
| Isofraxidin | ↓ invasion in HCC cells | ↓ MMP-7 and ERK1/2 | [ | |||
| β-Ionone | ↓ invasion, migration and adhesion in SK-Hep-1 cells | ↓ MMP-2 and -9, urokinase-type plasminogen activator activities, FAK, Rho, Rac1 and Cdc42, ↑ TIMP-1 and -2, plasminogen activator inhibitor-1 and nm23-H1 | [ | |||
| Hesperidin | ↓ acetaldehyde-induced cell invasion in HepG2 cells | ↓ MMP-9, NF-kappaB, AP-1, JNK, and p38 signaling pathways | [ | |||
| Astragalosides, | ↓ TGF-beta(1)-induced cell invasion in HepG2 cells | Modulating TGF-beta/Smad signaling | [ | |||
| ↑anti-tumor effect of Adriamycin in H22 hepatocarcinoma | ↑ IL-1α, IL-2, IL-6 and TNF-α, ↓ IL-10 and MDR1 | [ | ||||
| Tetramethylpyrazine | Reverse multidrug resistance in BEL-7402/ADM cells | ↓ MDR1, MRP2, MRP3 and MRP5 | [ | |||
| Epicatechin gallate and epigallocatechin gallate | Tea | Increase intracellular DOX accumulation and enhance DOX-induced cell killing activities against BEL-7404/DOX cells | ↓ MDR1 | [ | ||
| Hedyotiscone A | ↑ apoptosis in multidrug-resistant hepatocellular carcinoma cells | ↑ caspases-3, -7 and -9 | [ | |||
| Polyphyllin D | ↑ apoptosis in multi-drug resistant HepG2 cells | Mitochondrial dysfunction | [ | |||
| Ursolic acid | ↑ apoptosis in doxorubicin-resistant human hepatoma cells | ↑ Bak and apoptosis-inducing factor | [ | |||
| Pseudolaric acid B | ↑ apoptosis and arrest cell cycle at G2/M phase in conventional and P-gp-overexpressing hepatocarcinoma cells | Disrupts cellular microtubule networks and inhibits the formation of mitotic spindles | [ | |||
| Imperatorin | ↑ apoptosis in multidrug-resistant liver cancer cells | ↑ proteosome-dependent Mcl-1 degradation to release Bak and Bax | [ | |||
↓ Inhibit or down-regulate, ↑ promote or up-regulate.
Effects of herbal compounds on immune function and angiogenesis in hepatocarcinoma.
| Compounds | Herbs | Effects | Targets/Molecular Events | Ref. |
|---|---|---|---|---|
| ↑ CD4+ and CD8+ T cells in H22 hepatoma; promote dendritic cells to stimulate allogeneic lymphocyte proliferation, produce IL-12p70 and IFN-γ | Unknown; NF-κB | [ | ||
| Polysaccharides | ↑ CD4+ and CD8+ T cells, IFN-γ and IL-4 secretion, and induce cancer cell apoptosis in human hepatoma 7402 bearing mice | Unknown | [ | |
| Gastrodin | ↑ cytotoxic activities of NK and CD8+ T cells against H22 cells | ↑ NF-κB, IL-2 and Bcl-2 in CD4+ T cells | [ | |
| Shikonin | ↑ CD3+ and CD19+ lymphocytes, NK activities and IL-2 in HepA22 bearing mice | Unknown | [ | |
| Proteins extract | ↑ spleen mass and IFN-γ production in H22 hepatocarcinoma bearing mice | Unknown | [ | |
| Restore the defective biorheological characteristics of dendritic cells mediated by SMMC-7721 cells | Unknown | [ | ||
| ↓ proliferation and migration in CD4+ CD25+ Treg cells | ↓ Foxp3, SDF-1 or its receptor through the CXCR4/CXCL12 pathway | [ | ||
| Polysaccharide | ↓ Tregs cells | ↓ Foxp3 | [ | |
| ↓ bFGF stimulated proliferation and migration of endothelial cells, angiogenesis and tumor growth in liver cancer | ↓ bFGF secretion and binding to heparin/heparan sulfate | [ | ||
| Pedicularioside G | ↓ proliferation and migration in HUVEC cells, and angiogenesis in chicken embryo chorioallantoic membrane and hepatoma | ↓ reactive oxygen species | [ | |
| Vitexin compound 1 | ↓ proliferation and cell cycle arrest at G1/G0 in hepatocellular carcinoma cells, and HUVEC tube formation | ↓ VEGF | [ | |
| Resveratrol | ↓ proliferation in liver cancer cells | ↓ hypoxia-induced activation of ERK1/2 and Akt, HIF-1α and VEGF expression | [ | |
| Cinobufotalin, Panax notoginseng saponins, Ginsenosides Rg3 and Lentinan | ↓ angiogenesis and tumor growth in H22 hepatocellular carcinoma | ↓ VEGF, EGFR and MMP-2 expression | [ |
↓ Inhibit or down-regulate, ↑ promote or up-regulate.
Herbal compound-based combinational treatment.
| Compounds | Herbs | Effects | Targets/Molecular Events | Ref. |
|---|---|---|---|---|
| Astragalosides, Astragalus polysaccharide and salvianolic acids | ↓ DEN induced hepatocarcinogenesis; ↓ TGF-β1-induced cell invasion in HepG2 cells | ↓ GST-P and α-SMA; modulating TGF-β/Smad signaling | [ | |
| Cinobufotalin, Panax notoginseng saponins, Ginsenosides Rg3 and Lentinan | ↓ angiogenesis and tumor growth in H22 hepatocellular carcinoma | ↓ VEGF, EGFR and MMP-2 expression | [ | |
| Curcumin and resveratrol | ↓ proliferation, ↑ apoptosis in Hepa1-6 cells | ↓ XIAP and Survivin, ↑ ROS production, caspase-3, -8 and -9 | [ | |
| Cinobufotalin, Cantharidin, Panax notoginseng saponins, Tanshinone, Ginsenosides Rg3 and Lentinan | Inhibit tumor growth, prolong survival time, enhance anticancer effects and reduce toxicity of cisplatin in hepatocellular carcinoma bearing mice | Unknown | [ | |
| Acetylshikonin and β,β-dimethylacrylshikonin | ↓ proliferation, ↑ apoptosis, arrest cell cycle in G2/M phase in SMMC-7721 cells | ↓ Bcl-2 and Bcl-2/Bax ratio | [ |
↓ Inhibit or down-regulate, ↑ promote or up-regulate.